Beatrix Stelte‐Ludwig

Anetumab Ravtansine: A Novel Mesothelin-Targeting Antibody–Drug Conjugate Cures Tumors with Heterogeneous Target Expression Favored by Bystander Effect

Sven Golfier, Charlotte Kopitz, Antje Kahnert et al. · Molecular Cancer Therapeutics · 2014 · 245 citations

Pre‐clinical evidence for the use of phosphodiesterase‐5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptoms

Hanna Tinel, Beatrix Stelte‐Ludwig, Joachim Hütter et al. · British Journal of Urology · 2006 · 156 citations

Preclinical Efficacy of the Auristatin-Based Antibody–Drug Conjugate BAY 1187982 for the Treatment of FGFR2-Positive Solid Tumors

Anette Sommer, Charlotte Kopitz, Christoph A. Schatz et al. · Cancer Research · 2016 · 73 citations

Pathology, Tumor Biology, Preclinical Efficacy +16

Anetumab ravtansine inhibits tumor growth and shows additive effect in combination with targeted agents and chemotherapy in mesothelin-expressing human ovarian cancer models

Maria Quanz, Urs B. Hagemann, Sabine Zitzmann-Kolbe et al. · Oncotarget · 2018 · 56 citations · Full text

Preclinical Antitumor Efficacy of BAY 1129980—a Novel Auristatin-Based Anti-C4.4A (LYPD3) Antibody–Drug Conjugate for the Treatment of Non–Small Cell Lung Cancer

Jörg Willuda, Lars Lindén, Hans‐Georg Lerchen et al. · Molecular Cancer Therapeutics · 2017 · 45 citations